By: Jocelyn Solis-Moreira, MS Posted: Thursday, August 6, 2020 On August 5, the U.S. Food and Drug Administration (FDA) approved the antibody drug-conjugate belantamab mafodotin-blmf (Blenrep) for treatment of adults with relapsed or refractory multiple myeloma. Drug eligibility includes patients who have had…